Key Points
- CEO Xingjuan Chao sold 39,000 shares on May 5 at an average price of $20.10 for proceeds of $783,900, cutting her stake by 4.46% to 836,347 shares (about $16.8M).
- The May sale is part of a string of recent insider disposals — Chao also sold 39,000 shares on April 6 ($18.40) and March 3 ($17.45), plus a smaller February sale — indicating ongoing insider selling activity.
- Context: CeriBell has a market cap of roughly $772M, reported a Q4 loss of $0.36 per share while beating estimates on EPS and revenue, carries negative margins, and holds an average analyst rating of Moderate Buy with a $23.20 target.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $20.10, for a total transaction of $783,900.00. Following the sale, the chief executive officer owned 836,347 shares of the company's stock, valued at approximately $16,810,574.70. This trade represents a 4.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Xingjuan Chao also recently made the following trade(s):
- On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00.
- On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $17.45, for a total transaction of $680,550.00.
- On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $41,242.36.
CeriBell Price Performance
CeriBell stock opened at $20.38 on Friday. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The firm has a 50 day moving average price of $19.17 and a 200 day moving average price of $18.71. The company has a market cap of $771.83 million, a price-to-earnings ratio of -13.86 and a beta of 0.99. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The firm had revenue of $24.78 million for the quarter, compared to analysts' expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Sell-side analysts predict that CeriBell, Inc. will post -1.44 earnings per share for the current year.
Institutional Trading of CeriBell
Several institutional investors have recently added to or reduced their stakes in CBLL. Strs Ohio acquired a new stake in CeriBell in the first quarter valued at $27,000. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell during the third quarter valued at $33,000. CWM LLC increased its stake in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. BTIG Research reissued a "buy" rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CeriBell in a report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $23.20.
Read Our Latest Stock Report on CeriBell
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
